Form 4: Twist Bioscience Director Robert Chess Sells Shares to Cover Tax Obligations

Robert Chess, a director at Twist Bioscience Corp, sold 2,940 shares of common stock on February 7, 2025, to cover tax liabilities related to vesting Restricted Stock Units.

Summary

• On February 7, 2025, Robert Chess, a director of Twist Bioscience Corp, sold 2,940 shares of common stock.
• The sale was executed at a price of $53.135 per share.
• The transaction was conducted to cover tax liabilities associated with the vesting of Restricted Stock Units.
• Following the transaction, Robert Chess directly owns 18,173 shares of Twist Bioscience Corp.
• Additionally, he indirectly owns 42,528 shares through the Chess 1997 Trust, where he and his spouse are the sole trustees and beneficiaries.

Sentiment

Score: 6

Explanation: The document reflects a routine transaction (stock sale to cover taxes) by a company director. It doesn't indicate any significant positive or negative sentiment regarding the company's performance or future prospects.

Positives

• The sale was part of a pre-planned transaction to cover tax liabilities, indicating responsible financial planning by the director.

Industry Context

Sales of shares by company insiders are a common occurrence, often related to compensation or personal financial planning. The fact that this sale was to cover tax liabilities related to vesting RSUs suggests it's a routine transaction.

Comparison to Industry Standards

• Director stock sales are a regular part of corporate governance.
• Companies like Illumina, Thermo Fisher Scientific, and Danaher also see insider transactions as part of their executive compensation packages.
• The sale of shares to cover tax obligations is a standard practice among executives receiving stock-based compensation.

Stakeholder Impact

• The transaction is unlikely to have a significant impact on stakeholders as it is a routine sale to cover tax obligations.

Key Dates